MX360347B - Anticuerpo anti-inmunoglobulina g1 humana. - Google Patents

Anticuerpo anti-inmunoglobulina g1 humana.

Info

Publication number
MX360347B
MX360347B MX2013001401A MX2013001401A MX360347B MX 360347 B MX360347 B MX 360347B MX 2013001401 A MX2013001401 A MX 2013001401A MX 2013001401 A MX2013001401 A MX 2013001401A MX 360347 B MX360347 B MX 360347B
Authority
MX
Mexico
Prior art keywords
human igg1
igg1 antibody
antibody
specifically binding
immunoassays
Prior art date
Application number
MX2013001401A
Other languages
English (en)
Other versions
MX2013001401A (es
Inventor
Stubenrauch Kay-Gunnar
Vogel Rudolf
Wessels Uwe
Essig Ulrich
Klostermann Stefan
Kowalewsky Frank
Original Assignee
F Hoffmann La Roche Ag Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche Ag Star filed Critical F Hoffmann La Roche Ag Star
Publication of MX2013001401A publication Critical patent/MX2013001401A/es
Publication of MX360347B publication Critical patent/MX360347B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a un anticuerpo monoclonal que se une específicamente a un anticuerpo de IgG1 humana y no se une específicamente a la inmunoglobulina de un animal experimental, y el uso del anticuerpo en inmunoensayos.
MX2013001401A 2010-08-17 2011-08-12 Anticuerpo anti-inmunoglobulina g1 humana. MX360347B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10173090 2010-08-17
PCT/EP2011/063906 WO2012022682A1 (en) 2010-08-17 2011-08-12 Anti-human igg1 antibody

Publications (2)

Publication Number Publication Date
MX2013001401A MX2013001401A (es) 2013-04-03
MX360347B true MX360347B (es) 2018-10-30

Family

ID=43414794

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001401A MX360347B (es) 2010-08-17 2011-08-12 Anticuerpo anti-inmunoglobulina g1 humana.

Country Status (11)

Country Link
US (2) US20140038210A1 (es)
EP (1) EP2606071B1 (es)
JP (1) JP5766286B2 (es)
KR (1) KR101566090B1 (es)
CN (1) CN103068852B (es)
BR (1) BR112012033163A2 (es)
CA (2) CA3043423A1 (es)
HK (1) HK1184470A1 (es)
MX (1) MX360347B (es)
RU (1) RU2603284C2 (es)
WO (1) WO2012022682A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101536388B1 (ko) 2009-10-19 2015-07-22 에프. 호프만-라 로슈 아게 비-교차반응성 항-ＩｇＧ 항체
CA3043423A1 (en) 2010-08-17 2012-02-23 F. Hoffmann-La Roche Ag Anti-human igg1 antibody
US11085937B2 (en) 2015-09-24 2021-08-10 Bloodworks Composition and methods for assessing sensitivity and specificity of antibody detection reagents
EP3176580A1 (en) 2015-12-01 2017-06-07 Roche Diagnostics GmbH Method for reduction of interferences in immunoassays
EA201891366A1 (ru) * 2015-12-09 2018-12-28 Корвус Фармасьютикалз, Инк. Гуманизированные антитела против cd73
WO2019030202A1 (en) 2017-08-08 2019-02-14 F. Hoffmann-La Roche Ag METHOD FOR DETECTION OF ANTI-MEDICATION ANTIBODIES IN A MINI-PORK SAMPLE
CN112010981B (zh) * 2020-09-10 2021-05-18 南京妙迪生物科技有限公司 一种小鼠抗人IgG单克隆抗体
BR112023018399A2 (pt) * 2021-03-12 2024-02-06 Univ Rockefeller Nanocorpos específicos de glicoforme e métodos de uso

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2095818B (en) 1981-03-27 1985-10-02 Exxon Research Engineering Co Staged adsorption/resorption heat pump
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6468398A (en) 1987-09-08 1989-03-14 Agency Ind Science Techn Monoclonal anti-idiotype antibody and hybridoma and use thereof
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
US5332665A (en) 1991-12-18 1994-07-26 The General Hospital Corporation Species specific, high affinity monoclonal antibodies
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
GB9316841D0 (en) 1993-08-13 1993-09-29 Lucas Ind Plc Optical torque sensor incorporating sensor failure diagnostics
EP0938334A4 (en) 1996-07-26 2004-12-15 Smithkline Beecham Corp IMPROVED METHOD FOR TREATING IMMUNE-MEDIATED SYSTEMIC DISEASES
US6525174B1 (en) 1997-06-06 2003-02-25 Human Genome Sciences, Inc. Precerebellin-like protein
US6413783B1 (en) 1997-09-18 2002-07-02 Meso Scale Technologies, Llc Assay sonication apparatus and methodology
IT1315254B1 (it) 1999-11-05 2003-02-03 Diesse Diagnostica Senese Spa Metodo per la determinazione qualitativa e quantitativa di anticorpiumani di classe igc.
AUPR617901A0 (en) 2001-07-06 2001-08-02 Pacmab Pty Ltd Method for treating multiple myeloma
US7718387B2 (en) 2001-09-20 2010-05-18 Board Of Regents, The University Of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
JP4636225B2 (ja) 2002-11-30 2011-02-23 司甫 横山 検査試薬キット
EP1634606A1 (en) 2003-03-31 2006-03-15 Kyowa Hakko Kogyo Co., Ltd. Drug for airway administration
JP4473257B2 (ja) 2003-04-02 2010-06-02 エフ．ホフマン−ラ ロシュ アーゲー インスリン様成長因子ｉ受容体に対する抗体及びその使用
AR046071A1 (es) 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
AR045614A1 (es) 2003-09-10 2005-11-02 Hoffmann La Roche Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
NZ549872A (en) 2004-04-13 2009-09-25 Hoffmann La Roche Anti-P-selectin antibodies
AU2005241431A1 (en) 2004-04-16 2005-11-17 Genentech, Inc. Assay for antibodies
WO2006066912A2 (en) * 2004-12-23 2006-06-29 F. Hoffmann-La Roche Ag Detection of a therapeutic antibody in an experimental animal
TW200902555A (en) 2005-01-03 2009-01-16 Hoffmann La Roche Antibodies against IL-13 receptor alpha 1 and uses thereof
EP2221619A1 (en) 2006-09-12 2010-08-25 F. Hoffmann-La Roche AG Anti-drug antibody assay
KR101536388B1 (ko) 2009-10-19 2015-07-22 에프. 호프만-라 로슈 아게 비-교차반응성 항-ＩｇＧ 항체
CA3043423A1 (en) 2010-08-17 2012-02-23 F. Hoffmann-La Roche Ag Anti-human igg1 antibody

Also Published As

Publication number Publication date
JP5766286B2 (ja) 2015-08-19
US20150323543A1 (en) 2015-11-12
BR112012033163A2 (pt) 2016-10-11
KR20130041948A (ko) 2013-04-25
JP2013535482A (ja) 2013-09-12
EP2606071B1 (en) 2019-12-18
MX2013001401A (es) 2013-04-03
CN103068852A (zh) 2013-04-24
WO2012022682A1 (en) 2012-02-23
RU2603284C2 (ru) 2016-11-27
CA3043423A1 (en) 2012-02-23
US20140038210A1 (en) 2014-02-06
US9766251B2 (en) 2017-09-19
CN103068852B (zh) 2016-04-20
KR101566090B1 (ko) 2015-11-13
EP2606071A1 (en) 2013-06-26
RU2013109173A (ru) 2014-09-27
CA2806851C (en) 2019-12-03
CA2806851A1 (en) 2012-02-23
HK1184470A1 (zh) 2014-01-24

Similar Documents

Publication Publication Date Title
MX2013001401A (es) Anticuerpo anti-inmunoglobulina g1 humana.
GB2488091A (en) Humanized anti-interleukin 3 receptor alpha chain antibodies
HK1219965A1 (zh) 對磷脂醯肌醇蛋白聚糖 特異的人單克隆抗體及其用途
MX2012003825A (es) Anticuerpos anti igg reactivos no cruzados.
MX2015008740A (es) Variantes de regiones fc de igg1 de humano y usos de las mismas.
EA201270228A1 (ru) Полноценные человеческие антитела к btla
MX2019014658A (es) Anticuerpos humanizados que reconocen la alfa-sinucleina.
WO2013144566A3 (en) Animals expressing human lambda immunoglobulin light chain variable domain
MX341958B (es) Anticuerpos contra el il33r humano y usos de los mismos.
PT2569013T (pt) Anticorpos monoclonais humanizados e quiméricos para cd47
IL211742A (en) Isolated monoclonal antibodies specifically associated with frizzled receptor and various aspects thereof
PL2510011T3 (pl) Przeciwciała monoklonalne, które wiążą B7H6 i ich zastosowania
NZ602294A (en) Monoclonal antibodies against c-met
UA107574C2 (ru) Гуманизированное антитело, специфическое к протофибрилярной формы бета-амилоидного пептида
IL222359A0 (en) Monoclonal antibodies against her2 antigens, and uses therefor
PL2542575T3 (pl) Ekspresja przeciwciał monoklonalnych u tetrahymena
EP2593475A4 (en) ANTI-ADDL MONOCLONAL ANTIBODY AND USES THEREOF
DK2623592T3 (da) Anti-humane ccr7-antistoffer, hybridom, medicinsk sammensætning og antistof-immobiliseret bærer
WO2012006341A8 (en) Anti-ron antibodies
MX343580B (es) Anticuerpos contra el g-csfr y sus usos.
EP2540744A4 (en) TOTALLY HUMAN MONOCLONAL ANTIBODY AGAINST VEGF, PREPARATION METHOD AND APPLICATION THEREOF
ZA202104356B (en) Monoclonal antibodies that bind specifically to human trbv9
EP2575882A4 (en) HUMANIZED MONOCLONAL ANTIBODIES AND METHODS OF USE
EP2545075A4 (en) HUMANIZED AND CHIMERIC ANTI-PROPERDINE ANTIBODIES
MX2016005854A (es) Anticuerpo anti-her3 alosterico de la neuregulina.

Legal Events

Date Code Title Description
FG Grant or registration